Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 7,827 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Acute Disease Clear all

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Interventions: SC-DARIC33; Biological
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: Up to 30 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2041
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: COVID 19, SARS-CoV 2, Pneumonia
Interventions: Mavrilimumab, Placebo; Drug
Lead sponsor: Kristin Hudock; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Acute Respiratory Distress Syndrome, Pulmonary Hypertension
Interventions: Nitric Oxide; Drug
Lead sponsor: Yuri Matusov; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COVID 19 Disease
Interventions: Tafenoquine Oral Tablet, Placebo; Drug
Lead sponsor: 60 Degrees Pharmaceuticals LLC; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: Miami, Florida • Elkhorn, Nebraska • Morgantown, North Carolina + 4 more

Conditions: Leukemia, Lymphoma, Psychosocial Effects of Cancer and Its Treatment, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: complementary or alternative medicine procedure, management of therapy complications, psychosocial assessment and care; Procedure
Lead sponsor: Leap of Faith Technologies; Industry
Eligibility: 10 Years to 15 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Crystal Lake, Illinois

Conditions: Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions: STI571 400 mg, STI571 600 mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2013
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Portland, Oregon + 1 more

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 4
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: busulfan, carboplatin, carmustine, cyclophosphamide, etoposide, melphalan, thiotepa, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 4 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Leukemia, AML, MDS, CML
Interventions: Cytarabine, Fludarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Kidney Injury
Interventions: AKI Prevention Toolkit, Technical Assistance (TA), Virtual Learning Collaborative (VLC), Automated Surveillance Reporting (ASR); Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: Not listed
Enrollment: 10,252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Nashville, Tennessee • White River Junction, Vermont

Conditions: Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions: Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 15
States / cities: Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: alemtuzumab, cyclosporine, fludarabine phosphate, melphalan, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 24
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 19 more

Conditions: Germline Mutation, Myelodysplastic Syndromes, Acute Myeloid Leukemia
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Month to 120 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer, Nausea, Vomiting
Interventions: granisetron transdermal system, fosaprepitant dimeglumine, laboratory biomarker analysis; Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia ALL
Interventions: 4A10; Drug
Lead sponsor: Allterum Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Aurora, Colorado • Indianapolis, Indiana • New York, New York + 4 more

Conditions: Leukemia
Interventions: White Blood Cell Transfusion; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myocardial Infarction
Interventions: KAI-9803 for Injection, Placebo; Drug
Lead sponsor: KAI Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Post COVID-19, Cognitive Dysfunction
Interventions: Parasym Device (of Parasym Ltd, UK) using Transcutaneous Vagus Nerve Stimulation (t-VNS); Device
Lead sponsor: Casa Colina Hospital and Centers for Healthcare; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Pomona, California

Conditions: Acute Coronary Syndrome
Interventions: Not listed
Lead sponsor: Chattanooga-Hamilton County Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Ph-Like Acute Lymphoblastic Leukemia, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Transient Ischemic Attack
Interventions: Telestroke; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Burnsville, Minnesota • Grand Rapids, Minnesota • Hibbing, Minnesota + 2 more

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide, Phosphate Buffer Saline (PBS),; Drug
Lead sponsor: Shire; Industry
Eligibility: 10 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Wheaton, Maryland

Conditions: Long COVID, Post-Acute COVID-19 Syndrome
Interventions: Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling, Medications for symptoms management; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 20 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Covid-19
Interventions: ID NOW vs. Accula; Diagnostic Test
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 95 Years
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Search by objective public record fields.

PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension

Tafenoquine in Patients With Mild to Moderate COVID-19

Study of @neWorld: A Virtual Community for Children With Cancer

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

Long-Term Results in Mechanically Ventilated Individuals With Acute Lung Injury/Acute Respiratory Distress Syndrome

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

IMPROVE AKI Cluster-Randomized Trial

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

A Feasibility Study of Prophylactic White Blood Cell Transfusions

Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack

Multimodal Investigation of Post COVID-19 in Females

Usefulness of a 2-hour Delta Troponin-I During the ED Identification and Exclusion of Acute Myocardial Infarction

CD19-Specific T Cells Post AlloSCT

Telestroke for Comprehensive Transient Ischemic Attack Care in Acute Stroke Ready Hospitals

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid

Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19